Clarity Pharmaceuticals Ltd (CU6) - Total Assets
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) holds total assets worth AU$101.17 Million AUD (≈ $71.59 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CU6 total equity for net asset value and shareholders' equity analysis.
Clarity Pharmaceuticals Ltd - Total Assets Trend (2018–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
Clarity Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Clarity Pharmaceuticals Ltd's total assets of AU$101.17 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$29.41 Million | 47.1% |
| Accounts Receivable | AU$10.10 Million | 10.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$552.46K | 0.6% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CU6 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clarity Pharmaceuticals Ltd's current assets represent 99.4% of total assets in 2025, an increase from 97.8% in 2018.
- Cash Position: Cash and equivalents constituted 47.1% of total assets in 2025, down from 60.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is cash and equivalents at 47.1% of total assets.
Clarity Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Clarity Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Clarity Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.69 | 19.05 | 9.56 |
| Quick Ratio | 9.69 | 19.05 | 9.56 |
| Cash Ratio | 2.83 | 1.88 | 0.00 |
| Working Capital | AU$90.23 Million | AU$145.97 Million | AU$8.11 Million |
Clarity Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Clarity Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.79 |
| Latest Market Cap to Assets Ratio | 7.55 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | AU$101.17 Million |
| Market Capitalization | $763.38 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Clarity Pharmaceuticals Ltd's assets at a significant premium (7.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Clarity Pharmaceuticals Ltd's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clarity Pharmaceuticals Ltd (2018–2025)
The table below shows the annual total assets of Clarity Pharmaceuticals Ltd from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$101.17 Million ≈ $71.59 Million |
-34.57% |
| 2024-06-30 | AU$154.63 Million ≈ $109.41 Million |
+101.09% |
| 2023-06-30 | AU$76.90 Million ≈ $54.41 Million |
-22.97% |
| 2022-06-30 | AU$99.82 Million ≈ $70.63 Million |
+341.44% |
| 2021-06-30 | AU$22.61 Million ≈ $16.00 Million |
+148.08% |
| 2020-06-30 | AU$9.12 Million ≈ $6.45 Million |
-12.04% |
| 2019-06-30 | AU$10.36 Million ≈ $7.33 Million |
+271.88% |
| 2018-06-30 | AU$2.79 Million ≈ $1.97 Million |
-- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more